Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP7 | Q93009 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 6/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.38 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.38 |
| ▸ | CA9 | Q16790 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16671510 | 0.87 | USP7 (0.45) | USP7GPBAR1PTPN1PRKCDCA9 | |
| SCHEMBL16669528 | 0.87 | USP7 (0.45) | USP7GPBAR1PTPN1PRKCDCA9 | |
| SCHEMBL16669589 | 0.79 | GPBAR1 (0.32) | USP7GPBAR1 | |
| SCHEMBL16669216 | 0.75 | NT5E (0.47) | USP7GPBAR1PTPN1PRKCD | |
| SCHEMBL16669545 | 0.74 | NT5E (0.42) | USP7GPBAR1PTPN1PRKCD | |
| SCHEMBL16669687 | 0.72 | USP7 (0.38) | USP7GPBAR1PTPN1PRKCD | |
| SCHEMBL16669357 | 0.72 | USP7 (0.38) | USP7GPBAR1PTPN1PRKCD | |
| SCHEMBL16669204 | 0.72 | RORC (0.54) | USP7GPBAR1PTPN1PRKCD | |
| SCHEMBL5448193 | 0.72 | SLC10A1 (0.40) | USP7GPBAR1PTPN1PRKCD | |
| SCHEMBL14124011 | 0.71 | USP7 (0.69) | USP7GPBAR1PTPN1PRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | HETERO LABS LIMITED (IN) | 2015-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119373-A1 | NOVEL BETULINIC ACID DERIVATIVES AS HIV INHIBITORS | BET1, PGGT1B, RABGGTB | USP7 3226/4885GPBAR1 311/4885PTPN1 4078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.